Vested and expected to vest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Prepaid clinical development costs
Prepaid Clinical Development Costs, Current
Represents the amount of consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
Range [Domain]
Statistical Measurement [Domain]
Gross Unrealized Losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Cover [Abstract]
Cover [Abstract]
Daiichi Sankyo Europe GmbH ("DSE")
Daiichi Sankyo Europe Gmbh [Member]
Member stands for the Daiichi Sankyo Europe GmbH ("DSE").
Net (decrease) increase in cash and cash equivalents
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Exclusive Developmental Activities
Exclusive Developmental Activities [Member]
Represents information pertaining to exclusive developmental activities.
Trading Symbol
Trading Symbol
Segment Reporting Information [Line Items]
Segment Reporting Information [Line Items]
All Trading Arrangements
All Trading Arrangements [Member]
Debt Instrument, Redemption, Period [Axis]
Debt Instrument, Redemption, Period [Axis]
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Net Income [Text Block]
Non-NEOs
Non-NEOs [Member]
Number of consecutive trading days
Number Of Consecutive Trading Days
Number Of Consecutive Trading Days
Maturity
Long-Term Debt, Term
Schedule of Earnings Per Share, Basic and Diluted
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Rule 10b5-1 Arrangement Adopted
Rule 10b5-1 Arrangement Adopted [Flag]
Awards Close in Time to MNPI Disclosures
Awards Close in Time to MNPI Disclosures [Table]
Debt instrument, convertible, conversion ratio
Debt Instrument, Convertible, Conversion Ratio
Common stock
Common Class A [Member]
Milestone amount for worldwide sales to receive the third payment
Milestone Amount for Worldwide Sales to Receive Third Payment
Milestone amount for worldwide sales to receive the Third Payment.
Pre Funded Warrant
Pre Funded Warrant [Member]
Pre Funded Warrant
Pay vs Performance Disclosure [Line Items]
Peer Group Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Cash Equivalents
Cash Equivalents [Member]
Debt Instrument, Redemption, Period [Domain]
Debt Instrument, Redemption, Period [Domain]
Three Largest Customers
Three Largest Customers [Member]
Represents the ten largest customers of the entity.
Accounts receivable
Increase (Decrease) in Accounts Receivable
Intangible assets
Intangible Assets, Net (Including Goodwill)
Inventories, net
Inventory, Policy [Policy Text Block]
Non-Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted [Flag]
Percentage of increase in royalty rate upon drawdown of third payment
Percentage of Increase in Royalty Rate Upon Drawdown of Third Payment
The percentage of increase in the Royalty Rate upon drawdown of the Third Payment.
Fair Value Measurements
Fair Value Disclosures [Text Block]
Placement fees
Payments for Repurchase of Private Placement
Award Timing Disclosures [Line Items]
Capitalized issuance costs
Royalty Sale Liability, Capitalized Issuance Costs
Royalty Sale Liability, Capitalized Issuance Costs
Other Performance Measure, Amount
Other Performance Measure, Amount
Credit Agreement
Credit Agreement [Member]
Credit Agreement
Purchase of capped call options associated with convertible notes
Payments for Derivative Instrument, Financing Activities
Class of Warrant or Right [Axis]
Class of Warrant or Right [Axis]
Operating lease liabilities
Operating Lease, Liability, Noncurrent
Collaborations with Third Parties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Segment Reporting
Segment Reporting, Policy [Policy Text Block]
Expiration term
Warrants and Rights Outstanding, Term
Deferred revenue from collaborations
Contract with Customer, Liability, Current
Price per share (in dollars per share)
Sale of Stock, Price Per Share
Plan Name [Domain]
Plan Name [Domain]
Dilutive common stock equivalents (in shares)
Weighted Average Number of Shares Outstanding, Diluted, Adjustment
Entity Tax Identification Number
Entity Tax Identification Number
Cumulative purchaser payment adjustment
Revenue Interests Payment On Which Agreement Terminates
Revenue Interests Payment On Which Agreement Terminates
Underlying common stock (in shares)
Treasury Stock, Shares, Acquired
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Money market funds
Money Market Funds [Member]
Interest expense for convertible notes, less amortization of debt issuance costs
Interest on Convertible Debt, Net of Tax
Period Two
Debt Instrument, Redemption, Period Two [Member]
Net cash (used in) provided by operating activities
Net Cash Provided by (Used in) Operating Activities
Aggregate Intrinsic Value
Share Based Compensation Arrangement by Share Based Payment Award Aggregate Intrinsic Value [Abstract]
Proceeds from stock offering, net
Sale of Stock, Consideration Received on Transaction
Interests reverted to company
Sale Of Future Royalties, Percentage Royalty Interests Reverted To Company Following Receipt Of Threshold Purchase Price Multiple
Sale Of Future Royalties, Percentage Royalty Interests Reverted To Company Following Receipt Of Threshold Purchase Price Multiple
Operating activities
Net Cash Provided by (Used in) Operating Activities [Abstract]
Treasury Stock
Treasury Stock, Common [Member]
Percent acquired
Sale Of Future Royalties, Percentage Royalty Interests Acquired
Sale Of Future Royalties, Percentage Royalty Interests Acquired
Cost of goods sold
Other Cost and Expense, Operating
Collaboration revenue
Collaboration Revenue [Member]
Represents the information pertaining to collaboration revenue.
Plan Name [Axis]
Plan Name [Axis]
Equity Components [Axis]
Equity Components [Axis]
Award Timing Method
Award Timing Method [Text Block]
Trading Arrangements, by Individual
Trading Arrangements, by Individual [Table]
Estimated Fair Value
Debt Securities, Available-for-Sale
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Insider Trading Policies and Procedures [Line Items]
Stock-based compensation capitalized into inventory
Share-Based Payment Arrangement, Amount Capitalized
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Milestone payments related to total net sales achievements
Future Payment Milestone, Sales Milestones
The total amount of potential future payments related to total net sales achievements for Otsuka in Japan.
Long-term debt
Other Long-Term Debt, Noncurrent
Adjustment to Compensation, Amount
Adjustment to Compensation Amount
Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Sale of Future Royalties
Sale of Future Royalties [Member]
Sale of Future Royalties
Payables and Accruals [Abstract]
Payables and Accruals [Abstract]
Compensation Amount
Outstanding Recovery Compensation Amount
Amount of subsequent installment, subject to regulatory approval
Amount of Subsequent Installment, Subject to Regulatory Approval
The amount of the subsequent installment which is subject to regulatory approval.
Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table
Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]
Entity Small Business
Entity Small Business
Company Selected Measure Amount
Company Selected Measure Amount
Payment of royalty sale liability issuance costs
Payments of Debt Issuance Costs
Tabular List, Table
Tabular List [Table Text Block]
Effective annual imputed interest rate
Sale Of Future Royalties, Effective Annual Imputed Interest Rate
Sale Of Future Royalties, Effective Annual Imputed Interest Rate
Level 3
Fair Value, Inputs, Level 3 [Member]
Stock compensation
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Selling, general and administrative
Selling and Marketing Expense [Member]
Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table
Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]
Warrants issued for shares of common stock (in shares)
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Investments
Debt Securities, Available-for-Sale [Line Items]
Vesting of ESPP Shares (in shares)
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Total potential dilutive shares (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Total amount of subsequent installment, subject to RIPA terms and conditions
Amount of Subsequent Installment, Subject to Revenue Interest Purchase Agreement Terms and Conditions
The total amount of the subsequent installment, subject to the terms and conditions of the Revenue Interest Purchase Agreement.
Exercise of warrants (in shares)
Stock Issued During Period, Shares, Warrant Exercises
Stock Issued During Period, Shares, Warrant Exercises
Consideration cash payment
Future Up-Front Payment
Future Up-Front Payment
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Accretion (amortization) of premiums and discounts on investments
Accretion (Amortization) of Discounts and Premiums, Investments
Current assets:
Assets, Current [Abstract]
Common stock purchasable under warrants (in shares)
Common Stock Purchasable Under Warrants
Common Stock Purchasable Under Warrants
Fair Value of Financial Instruments
Fair Value of Financial Instruments, Policy [Policy Text Block]
Inventories, net
Inventory Disclosure [Text Block]
Treasury stock (in shares)
Treasury Stock, Common, Shares
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Number of business days
Number Of Business Days
Number Of Business Days
Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2024
Revenue Interest Rate, Tier Two
The Revenue Interest Rate which will take effect if annual net sales equal or exceed $350.0 million by December 31, 2021.
Product and Service [Domain]
Product and Service [Domain]
Common shares under option
Common shares under option
Share-Based Payment Arrangement, Option [Member]
Debt Securities, Available-for-sale [Table]
Debt Securities, Available-for-Sale [Table]
Vested (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Debt instrument, convertible, threshold percentage of last reported sale price
Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price
Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Abstract]
Depreciation expense
Depreciation
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Security, Excluded EPS Calculation [Table]
Comprehensive (loss) income
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Preferred stock, outstanding (in shares)
Preferred Stock, Shares Outstanding
Warrants
Warrant [Member]
Security Exchange Name
Security Exchange Name
Award Type [Axis]
Award Type [Axis]
Quarterly principal payment rate after four years
Debt Instrument, Quarterly Principal Rate After Four Years
Debt Instrument, Quarterly Principal Rate After Four Years
Revenue interest rate if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024
Revenue Interest Rate, Tier Three
The Revenue Interest Rate which will take effect if annual net sales equals or exceeds the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024.
Common stock purchasable under prefunded warrants (in shares)
Common Stock Purchasable Under Prefunded Warrants
Common Stock Purchasable Under Prefunded Warrants
Milestone payment upon JNDA Approval in the Otsuka Territory
Future Payment Milestone, First Submission of Japanese New Drug Application, Otsuka Territory
The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory.
Reclassification out of Accumulated Other Comprehensive Income
Reclassification out of Accumulated Other Comprehensive Income [Member]
Exercised (in dollars per share)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Number of RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Convertible Senior Notes Due 2030, Exchange Transactions
Convertible Senior Notes Due 2030, Exchange Transactions [Member]
Convertible Senior Notes Due 2030, Exchange Transactions
Work in process
Inventory, Work in Process, Net of Reserves
Property and equipment, net
Property, Plant and Equipment, Net
Aggregate principal amount
Repayments of Debt
Total liabilities
Liabilities
Securities Purchase Agreement
Securities Purchase Agreement [Member]
Securities Purchase Agreement
Exercisable (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Convertible Debt
Convertible Debt [Member]
Common stock, par value (in dollars per share)
Common Stock, Par or Stated Value Per Share
Forgone Recovery, Explanation of Impracticability
Forgone Recovery, Explanation of Impracticability [Text Block]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule of Company's Cash Equivalents and Short-Term Investments
Unrealized Gain (Loss) on Investments [Table Text Block]
Expiration Date
Trading Arrangement Expiration Date
Basis spread on make-whole premium
Debt Instrument, Basis Spread On Make-Whole Premium In Next Two Years
Debt Instrument, Basis Spread On Make-Whole Premium In Next Two Years
Investing activities
Net Cash Provided by (Used in) Investing Activities [Abstract]
Operating lease liabilities
Operating Lease, Liability, Current
Total Shareholder Return Amount
Total Shareholder Return Amount
Common stock, issued (in shares)
Common Stock, Shares, Issued
Sale of Future Royalties
Sale Of Future Royalties Disclosure [Text Block]
Sale Of Future Royalties Disclosure
Debt instrument, convertible, threshold consecutive trading days
Debt Instrument, Convertible, Threshold Consecutive Trading Days
Number of notices received from pharmaceutical companies
Abbreviated New Drug Application Litigation, Number Of Notices Received
Abbreviated New Drug Application Litigation, Number Of Notices Received
Equity Awards Adjustments, Footnote
Equity Awards Adjustments, Footnote [Text Block]
Concentration risk
Concentration Risk, Percentage
Other accrued liabilities
Increase (Decrease) in Other Accrued Liabilities
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Adopted [Flag]
Exercised (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Scheduled trading days
Debt Instrument, Redemption Option, Period Prior To Maturity Date, Scheduled Trading Days
Debt Instrument, Redemption Option, Period Prior To Maturity Date, Scheduled Trading Days
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Named Executive Officers, Footnote
Named Executive Officers, Footnote [Text Block]
Research and development
Research and Development Expense [Member]
Weighted-Average Exercise Price Per Share
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Common stock, authorized (in shares)
Common Stock, Shares Authorized
Basis of Presentation
Basis of Accounting, Policy [Policy Text Block]
Weighted-average shares outstanding - diluted (in shares)
Weighted average shares - diluted (in shares)
Weighted Average Number of Shares Outstanding, Diluted
Other Nonoperating Income (Expense)
Other Nonoperating Income (Expense) [Member]
MNPI Disclosure Timed for Compensation Value
MNPI Disclosure Timed for Compensation Value [Flag]
Commitment Offering
Commitment Offering [Member]
Commitment Offering
Long-term Debt, Type [Axis]
Long-Term Debt, Type [Axis]
Convertible notes, net of issuance costs
Convertible Notes Payable, Current
Total stockholders’ deficit
Beginning balance
Ending balance
Equity, Attributable to Parent
Collaborations with Third Parties
Collaborative Arrangement Disclosure [Text Block]
Number of customers
Concentration Risk, Number of Customers
The number of the Company's customers.
Balance Sheet Location [Axis]
Statement of Financial Position Location, Balance [Axis]
Interest expense
Interest expense recognized
Interest Expense, Nonoperating
Concentration Risk Type [Domain]
Concentration Risk Type [Domain]
Prepayment premium during year four
Debt Instrument, Prepayment Premium, Year Four
Debt Instrument, Prepayment Premium, Year Four
Selling, general and administrative
Selling, General and Administrative Expense
Repayment of convertible notes
Repayments of Convertible Debt
Recurring fair value measurement
Fair Value, Recurring [Member]
Accounts receivable, net
Accounts Receivable, after Allowance for Credit Loss, Current
Debt instrument, convertible, conversion price (in dollars per share)
Debt Instrument, Convertible, Conversion Price
Granted (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Purchase discount
Employee Stock Purchase Plan, Percentage Discount on Shares
The discount at which shares may be purchased under the employee stock purchase plan, calculated as a stated percentage of the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period.
Product sales, net
Product [Member]
Amount of long-term capitalized issuance costs to be amortized
Royalty Sale Liability, Capitalized Issuance Costs, Amortized Expense, Year Two And Thereafter
Royalty Sale Liability, Capitalized Issuance Costs, Amortized Expense, Year Two And Thereafter
Net (Loss) Income Per Common Share
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of commons stock shares available for issuance (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Sale of Stock [Domain]
Sale of Stock [Domain]
Long-term debt
Total
Long-Term Debt
Pension Adjustments Prior Service Cost
Pension Adjustments Prior Service Cost [Member]
Document Fiscal Period Focus
Document Fiscal Period Focus
2029
Long-Term Debt, Maturity, Year Four
All Executive Categories
All Executive Categories [Member]
Effect of dilutive common stock equivalents (in shares)
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements
Balance Sheet Location [Domain]
Statement of Financial Position Location, Balance [Domain]
Shares issuable upon conversion of convertible notes
Convertible Debt Securities [Member]
Changed Peer Group, Footnote
Changed Peer Group, Footnote [Text Block]
Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Assets
Assets [Abstract]
Proceeds from exercise of warrants, net of issuance costs
Proceeds from Warrant Exercises
Duration of offering periods
Employee Stock Purchase Plan, Duration of Offering Period
The duration of offering periods in which employees may purchase stock, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Document Type
Document Type
Vesting of restricted stock units and performance-based restricted stock units
Stock Issued During Period, Value, Restricted Stock Award, Gross
Pension Benefits Adjustments, Footnote
Pension Benefits Adjustments, Footnote [Text Block]
Total Shareholder Return Vs Peer Group
Total Shareholder Return Vs Peer Group [Text Block]
Estimated offering expenses
Payments for Commissions
Vesting of restricted stock units and performance-based restricted stock units (in shares)
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Vested (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Weighted-Average Remaining Contractual Term (Years)
Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]
Upfront cash payment received (paid)
Up-Front Payment
The amount of up-front payment received (paid) .
Adjustments for dilutive earnings per share:
Net Income (Loss) Attributable to Parent, Diluted [Abstract]
Maximum
Maximum [Member]
Equity Valuation Assumption Difference, Footnote
Equity Valuation Assumption Difference, Footnote [Text Block]
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Accounts payable
Accounts Payable, Current
Accounting Policies [Abstract]
Accounting Policies [Abstract]
Revenues:
Revenues [Abstract]
Remaining unamortized discount
Debt Instrument, Unamortized Discount
Pre Funded Warrant And Accompanying Warrant
Pre Funded Warrant And Accompanying Warrant [Member]
Pre Funded Warrant And Accompanying Warrant
Current Fiscal Year End Date
Current Fiscal Year End Date
Accrued interest receivable
Accrued Investment Income Receivable
Effect of dilutive common stock equivalents:
Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]
Statistical Measurement [Axis]
Statistical Measurement [Axis]
PEO Name
PEO Name
Total shares of common stock from exercisable warrants outstanding (in shares)
Class of Warrant or Right, Outstanding
Interest rate if paid in cash
Debt Instrument, Interest Rate, Paid in Cash
Debt Instrument, Interest Rate, Paid in Cash
Non-Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated [Flag]
Shares issued (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period
Inducement Equity Plan 2017
Inducement Equity Plan 2017 [Member]
Inducement Equity Plan 2017
Significant Accounting Policies [Table]
Significant Accounting Policies [Table]
Disclosure of information about significant accounting policies.
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Total Compensation Amount
Equity Award [Domain]
Award Type [Domain]
Name
Outstanding Recovery, Individual Name
Exchange Agreement, threshold trading days
Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days
Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days
Number of revenue sources
Number Of Sources Of Revenue
Number Of Sources Of Revenue
Consideration received
Royalty Sale, Consideration Received
Royalty Sale, Consideration Received
Schedule of Shares Excluded From Calculation of Diluted Net (Loss) Income Per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Compensation Actually Paid vs. Company Selected Measure
Compensation Actually Paid vs. Company Selected Measure [Text Block]
Non-PEO NEO
Non-PEO NEO [Member]
Option period
Sale Of Stock, Underwriter Option Period
Sale Of Stock, Underwriter Option Period
Daiichi Sankyo Co. Ltd
Daiichi Sankyo Co. Ltd [Member]
Daiichi Sankyo Co. Ltd
Additional Paid-In Capital
Additional Paid-in Capital [Member]
Award Timing Predetermined
Award Timing Predetermined [Flag]
License and Collaboration Agreement
Collaborative Arrangement [Member]
Debt instrument, redemption price, percentage
Debt Instrument, Redemption Price, Percentage
Recently Issued Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Class of Stock [Axis]
Class of Stock [Axis]
Net loss per common share - diluted (in dollars per share)
Net income (loss) per common share - diluted (in dollars per share)
Earnings Per Share, Diluted
Cash payment to the Company upon first commercial sales in the DSE Territory
Cash Payment to be Received upon First Commercial Sales
The amount of cash payment to the Company upon first commercial sales in the DSE Territory.
Counterparty Name [Domain]
Counterparty Name [Domain]
Name
Measure Name
Interest rate if paid-in-kind
Debt Instrument, Interest Rate, Paid In Kind
Debt Instrument, Interest Rate, Paid In Kind
First milestone payment
Settlement Agreement Aggregate First Milestone Payment From Partner
Settlement Agreement Aggregate First Milestone Payment From Partner
Entity Interactive Data Current
Entity Interactive Data Current
Deferred revenue
Increase (Decrease) in Contract with Customer, Liability
Transfer of assets between levels
Fair Value Measurement Asset Transfers between Levels
Represents the transfer of assets between the levels of fair value hierarchy that have taken place during the period.
Potential additional future payments
Aggregate Amount of Potential Future Revenue, Total Development and Sales Milestones
The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones.
Restatement does not require Recovery
Restatement Does Not Require Recovery [Text Block]
Number of operating segments
Number of Operating Segments
Preferred stock, issued (in shares)
Preferred Stock, Shares Issued
Customer [Axis]
Customer [Axis]
Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Statement of Financial Position [Abstract]
Statement of Financial Position [Abstract]
Aggregate payment agreement
Settlement Agreement Aggregate Payment From Partner
Settlement Agreement Aggregate Payment From Partner
Summary of Warrants and Pre-funded Warrants Outstanding
Summary Of Warrants And Pre Funded Warrants Outstanding [Table Text Block]
Summary Of Warrants And Pre Funded Warrants Outstanding
Stock-based compensation expense
Share-Based Payment Arrangement, Noncash Expense
One time partial call
One Time Partial Call
One Time Partial Call
Provision for income taxes
Income Tax Expense (Benefit)
Interest rate percentage
Debt Instrument, Interest Rate, Stated Percentage
Fair value of warrants
Adjustments to Additional Paid in Capital, Warrant Issued
Forfeited or expired (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
Supplemental disclosure of cash flow information:
Supplemental Cash Flow Information [Abstract]
Net (loss) income - diluted
Net Income (Loss) Available to Common Stockholders, Diluted
Weighted-average period over which remaining unrecognized compensation cost will be recognized
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Total Revenues
Revenue from Contract with Customer, Excluding Assessed Tax
Reclassification out of Accumulated Other Comprehensive Income [Domain]
Reclassification out of Accumulated Other Comprehensive Income [Domain]
Otsuka Pharmaceutical Co, Ltd.
Otsuka Pharmaceutical Co Ltd [Member]
Represents information pertaining to Otsuka Pharmaceutical Co, Ltd.
Concentration Risk Benchmark [Domain]
Concentration Risk Benchmark [Domain]
Collaborations with Third Parties
Collaborations with Third Parties
n/a
RIPA Amendment To The Security Agreement And Waiver
RIPA Amendment To The Security Agreement And Waiver [Member]
RIPA Amendment To The Security Agreement And Waiver
Net cash (used in) investing activities
Net Cash Provided by (Used in) Investing Activities
(Loss) income from operations
Operating Income (Loss)
Convertible Senior Notes Due 2025
Convertible Senior Notes Due 2025 [Member]
Convertible Senior Notes Due 2025
Research and development
Research and Development Expense (Excluding Acquired in Process Cost)
Number of reportable segments
Number of Reportable Segments
Total liabilities and stockholders’ deficit
Liabilities and Equity
Rule 10b5-1 Arrangement Terminated
Rule 10b5-1 Arrangement Terminated [Flag]
All Adjustments to Compensation
All Adjustments to Compensation [Member]
Accrued compensation
Employee-related Liabilities, Current
Fair Value Hierarchy and NAV [Axis]
Fair Value Hierarchy and NAV [Axis]
Prepaids and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Additional paid-in capital
Additional Paid in Capital
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]
Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]
Interest income on investments
Investment Income, Interest
Warrants expired (in shares)
Class Of Warrant Or Right, Expired
Class Of Warrant Or Right, Expired
Summary of Activity Relating to the Company's RSUs
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
Other accrued liabilities
Total other accrued liabilities
Accrued Liabilities and Employee-related Liabilities, Current
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Schedule of Estimated Future Principal Payments
Schedule of Maturities of Long-Term Debt [Table Text Block]
Underlying Security Market Price Change
Underlying Security Market Price Change, Percent
Individual:
Individual [Axis]
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent [Member]
Restricted cash
Restricted Cash
Inventories, net
Total Inventory
Inventory, Net
Trailing number of months sales must be at or above milestone amount
Trailing Number Of Months Sales Must Be At Or Above Milestone Amount
The trailing number of months sales must be at or above the milestone amount.
Long-term Debt, Type [Domain]
Long-Term Debt, Type [Domain]
Product and Service [Axis]
Product and Service [Axis]
Entity Address, State or Province
Entity Address, State or Province
Statement [Line Items]
Statement [Line Items]
Erroneous Compensation Analysis
Erroneous Compensation Analysis [Text Block]
Operating expenses:
Operating Expenses [Abstract]
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Total Shareholder Return [Text Block]
Financial Instruments [Domain]
Financial Instruments [Domain]
Outstanding and unvested at the beginning of period (in dollars per share)
Outstanding and unvested at the at the end of the period (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Convertible Senior Notes Due 2030
Convertible Senior Notes Due 2030 [Member]
Convertible Senior Notes Due 2030
Liabilities and stockholders’ deficit
Liabilities and Equity [Abstract]
Accrued legal fees
Accrued Legal Fees, Current
Accrued Legal Fees, Current
Minimum
Minimum [Member]
Restatement Determination Date
Restatement Determination Date
Vested and expected to vest (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Payments on revenue interest liability
Payments From Revenue Interest Purchase Agreement
The cash outflow from a revenue interest purchase agreement.
Adoption Date
Trading Arrangement Adoption Date
Pay vs Performance Disclosure
Pay vs Performance Disclosure [Table]
Outstanding at the beginning of period (in dollars per share)
Outstanding at the end of the period (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Right of use operating lease assets
Operating Lease, Right-of-Use Asset
Erroneously Awarded Compensation Recovery
Erroneously Awarded Compensation Recovery [Table]
Outstanding at the beginning of period (in shares)
Outstanding at the end of the period (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year
Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]
Long-term debt, gross
Long-Term Debt, Gross
Percentage of royalties to be received on the net sales
Percentage of Royalties to be Received on Net Sales
The percentage of royalties to be received on net sales.
Exercise Price
Award Exercise Price
Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received
Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received [Member]
Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received
Net (Loss) Income Per Common Share
Earnings Per Share [Text Block]
Arrangement Duration
Trading Arrangement Duration
Vesting of ESPP shares
Stock Issued During Period, Value, Employee Stock Purchase Plan
Trade Receivables
Trade Accounts Receivable [Member]
Stockholders’ deficit:
Equity, Attributable to Parent [Abstract]
Granted (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Warrants exercised (in shares)
Class of Warrant or Right, Exercised
Class of Warrant or Right, Exercised
Royalties recognized and settled to Purchaser
Royalty Sale Liability, Decrease for Royalties Recognized
Royalty Sale Liability, Decrease for Royalties Recognized
Royalty sale liability
Total royalty sale liability at December 31, 2024
Total royalty sale liability at March 31, 2025
Royalty Sale Liability
Royalty Sale Liability
Peer Group Issuers, Footnote
Peer Group Issuers, Footnote [Text Block]
Material Terms of Trading Arrangement
Material Terms of Trading Arrangement [Text Block]
Exchange Agreement, weighted average price per share floor (in dollars per share)
Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor
Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor
All Individuals
All Individuals [Member]
Prepaid Inventory Costs
Prepaid Inventory Costs
Prepaid Inventory Costs
PEO
PEO [Member]
Aggregate principal amount
Sale Of Future Royalties, Threshold Amount Purchaser Will Receive Prior To Interests Reverting Back To Company
Sale Of Future Royalties, Threshold Amount Purchaser Will Receive Prior To Interests Reverting Back To Company
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Abstract]
Debt instrument, fair value disclosure
Debt Instrument, Fair Value Disclosure
Debt instrument, required amount outstanding
Debt Instrument, Covenant, Required Amount Outstanding
Debt Instrument, Covenant, Required Amount Outstanding
Proceeds from milestone upon submission of a Japanese New Drug Application (JNDA) in the Otsuka Territory
Proceeds From Milestone Payment
Proceeds From Milestone Payment
Name
Trading Arrangement, Individual Name
Other income, net
Other Nonoperating Income (Expense)
Statement of Stockholders' Equity [Abstract]
Statement of Stockholders' Equity [Abstract]
Gross Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Unrecognized stock-based compensation expense, RSUs
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Treasury stock, at cost; 1,994,198 shares at March 31, 2025 and December 31, 2024
Treasury Stock, Common, Value
2025
Long-Term Debt, Maturity, Remainder of Fiscal Year
Awards Close in Time to MNPI Disclosures, Table
Awards Close in Time to MNPI Disclosures [Table Text Block]
Liability Related to the Sale of Future Royalties
Liability Related To The Sale Of Future Royalties [Policy Text Block]
Liability Related To The Sale Of Future Royalties
Shares reserved for future issuance (in shares)
Common Stock, Capital Shares Reserved for Future Issuance
Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year
Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]
Beginning balance (in shares)
Ending balance (in shares)
Shares, Outstanding
Threshold ratio of purchase price
Sale Of Future Royalties, Threshold Purchase Price Multiplier
Sale Of Future Royalties, Threshold Purchase Price Multiplier
Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Amount
Local Phone Number
Local Phone Number
Revenue Interest Purchase Agreement (RIPA)
Revenue Interest Purchase Agreement [Member]
Represents the information pertaining to revenue interest purchase agreement ("RIPA").
Aggregate Erroneous Compensation Not Yet Determined
Aggregate Erroneous Compensation Not Yet Determined [Text Block]
Repurchase consideration
Payments For Repurchase Of Revenue Interests
Payments For Repurchase Of Revenue Interests
Total operating expenses
Operating Expenses
Changes in assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Allowance for credit loss
Debt Securities, Available-for-Sale, Allowance for Credit Loss
PEO Total Compensation Amount
PEO Total Compensation Amount
Schedule of Other Accrued Liabilities
Schedule of Accrued Liabilities [Table Text Block]
Accrued interest on convertible notes
Interest Payable, Current
Income Statement Location [Axis]
Statement of Income Location, Balance [Axis]
Vested and expected to vest (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Cash and Cash Equivalents
Cash and Cash Equivalents, Policy [Policy Text Block]
Payment of issuance costs
Payments of Stock Issuance Costs
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Debt Disclosure [Abstract]
Common Stock
Common Stock [Member]
Measure:
Measure [Axis]
Time required to pay cash portion
Settlement Agreement, Time Required to Pay Cash Portion of Settlement
Settlement Agreement, Time Required to Pay Cash Portion of Settlement
Non-cash royalty revenue
Non Cash Royalty Revenue Related To Sale Of Future Royalties
Non Cash Royalty Revenue Related To Sale Of Future Royalties
Preferred stock, authorized (in shares)
Preferred Stock, Shares Authorized
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Expense of Enforcement, Amount
Issuance of common stock from offering, net of issuance costs (in shares)
Stock Issued During Period, Shares, New Issues
Additional consideration per amended warrant (in dollars per share)
Class of Warrant or Right, Exercise Price of Warrants or Rights, Additional Consideration
Class of Warrant or Right, Exercise Price of Warrants or Rights, Additional Consideration
Period One
Debt Instrument, Redemption, Period One [Member]
Line of Credit
Line of Credit [Member]
Entity Emerging Growth Company
Entity Emerging Growth Company
Issuance costs to additional paid in capital
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Segment Reporting [Abstract]
Entity Central Index Key
Entity Central Index Key
2030
Long-Term Debt, Maturity, Year Five
The Warrants
The Warrants [Member]
The Warrants
Schedule of Inventories
Schedule of Inventory, Current [Table Text Block]
Common stock exchanged (in shares)
Debt Conversion, Converted Instrument, Shares Issued
Non-GAAP Measure Description
Non-GAAP Measure Description [Text Block]
Non-PEO NEO Average Compensation Actually Paid Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Common shares under PBSOs
Common shares under PBSOs
Share Based Payment Arrangement, Option, Performance Based [Member]
Share Based Payment Arrangement, Option, Performance Based
Proceeds from Revenue Interest Purchase Agreement
Proceeds from Revenue Interest Purchase Agreement
Proceeds from Revenue Interest Purchase Agreement
Stockholders' Deficit
Equity [Text Block]
Award Timing, How MNPI Considered
Award Timing, How MNPI Considered [Text Block]
Equity Component [Domain]
Equity Component [Domain]
Preferred stock, par value (in dollars per share)
Preferred Stock, Par or Stated Value Per Share
Financial Instrument [Axis]
Financial Instrument [Axis]
Segment Reporting
Segment Reporting Disclosure [Text Block]
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Accrued variable consideration
Accrued Variable Consideration, Current
Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees
Additional 402(v) Disclosure
Additional 402(v) Disclosure [Text Block]
Specified net revenue
Specified Net Revenue Threshold Triggering Deposit In Blocked Account
Maximum Amount of Net Revenue To Qualify For Deposit In Blocked Account
Exercise of warrants
Stock Issued During Period, Value, Warrant Exercises
Stock Issued During Period, Value, Warrant Exercises
Stock-based compensation
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Entity Shell Company
Entity Shell Company
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Title
Trading Arrangement, Individual Title
Class of warrant or right, premium percentage
Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage
Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage
Aggregate principal amount
Debt Instrument, Repurchased Face Amount
Royalty sale liability
Royalty Sale Liability, NonCurrent
Royalty Sale Liability, NonCurrent
Statement [Table]
Statement [Table]
Debt interest expense
Interest Expense, Debt
Initial revenue interest rate
Revenue Interest Rate, Initial Rate
The initial revenue interest rate, as a percentage of the Company's net sales in the Covered Territory.
Fair Value, Measurement Frequency [Domain]
Measurement Frequency [Domain]
Counterparty Name [Axis]
Counterparty Name [Axis]
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Net (Loss) Income Per Common Share
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
City Area Code
City Area Code
Common Stock And Accompanying Warrant
Common Stock And Accompanying Warrant [Member]
Common Stock And Accompanying Warrant
Current liabilities:
Liabilities, Current [Abstract]
Minimum liquidity
Debt Instrument, Covenant, Minimum Liquidity
Debt Instrument, Covenant, Minimum Liquidity
Shares delivered to the company (in shares)
Stock Issued During Period, Shares, Treasury Stock Reissued
Accounts Receivable Risks
Accounts Receivable Risks [Member]
Accounts Receivable Risks
Revenue Recognition
Revenue [Policy Text Block]
Insider Trading Policies and Procedures Not Adopted
Insider Trading Policies and Procedures Not Adopted [Text Block]
Level 1
Fair Value, Inputs, Level 1 [Member]
Concentration Risk Benchmark [Axis]
Concentration Risk Benchmark [Axis]
Neopharm
Neopharm [Member]
Neopharm
Total current assets
Assets, Current
Statement of Cash Flows [Abstract]
Statement of Cash Flows [Abstract]
Exchange Agreement, amount of principal amount converted into common stock
Debt Conversion, Converted Instrument, Amount
Provision for income taxes
Income Tax Expense (Benefit), Continuing Operations [Abstract]
Prepayment of forward stock repurchase transaction
Payments for Repurchase of Common Stock
Exercisable (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
2028
Long-Term Debt, Maturity, Year Three
Second milestone payment
Settlement Agreement Aggregate Second Milestone Payment From Partner
Settlement Agreement Aggregate Second Milestone Payment From Partner
Schedule of Long-term Debt Instruments [Table]
Schedule of Long-Term Debt Instruments [Table]
Stock Option And Incentive Plan 2022
Stock Option And Incentive Plan 2022 [Member]
Stock Option And Incentive Plan 2022
Accrued clinical development costs
Accrued Clinical Development Costs, Current
Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).
Schedule of Segment Reporting Information, by Segment [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Weighted-Average Fair Value Per Share
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Original issue discount percentage
Debt Instrument, Original Discount (Premium), Percentage
Debt Instrument, Original Discount (Premium), Percentage
Non-cash right of use asset
Non Cash Right Of Use Asset
Represents the difference between the lease asset and the lease liability.
Liability Related to the Revenue Interest Purchase Agreement
Liability Related to the Revenue Interest Purchase Agreement
No definition.
Income Taxes
Income Tax Disclosure [Text Block]
Earnings Per Share [Abstract]
Earnings Per Share [Abstract]
Equity [Abstract]
Raw materials
Inventory, Raw Materials, Net of Reserves
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Class of Stock [Domain]
Class of Stock [Domain]
Forfeited or expired (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Inventories
Increase (Decrease) in Inventories
Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate
Percentage of Invested Capital Received By December 31, 2024, To Qualify For Second Reduced Revenue Interest Rate
Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate.
Schedule of Activity Within Royalty Sale Liability
Schedule of Debt [Table Text Block]
2027
Long-Term Debt, Maturity, Year Two
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Aggregate Available
Trading Arrangement, Securities Aggregate Available Amount
Equity Awards Adjustments
Equity Awards Adjustments [Member]
Net cash (used in) provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Underlying Securities
Award Underlying Securities Amount
Unvested PBRSUs
Unvested PBRSUs
Performance Shares [Member]
Sale of Future Royalties [Roll Forward]
Sale of Future Royalties [Roll Forward]
Sale of Future Royalties
Amendment Flag
Amendment Flag
Entity Registrant Name
Entity Registrant Name
Adjustment to Non-PEO NEO Compensation Footnote
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]
Stock Appreciation Rights (SARs)
Stock Appreciation Rights (SARs) [Member]
Warrants for common stock (in shares)
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Reclassification out of Accumulated Other Comprehensive Income [Axis]
Reclassification out of Accumulated Other Comprehensive Income [Axis]
Fair Value as of Grant Date
Award Grant Date Fair Value
Customer Concentration Risk
Customer Concentration Risk [Member]
Issued stock (in shares)
Sale of Stock, Number of Shares Issued in Transaction
Vested and expected to vest
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Debt issuance costs
Debt Issuance Costs, Net
Level 2
Fair Value, Inputs, Level 2 [Member]
Debt
Debt Disclosure [Text Block]
Fair Value Hierarchy [Domain]
Fair Value Hierarchy and NAV [Domain]
Gross proceeds from revenue interest liability
Gross Proceeds from Revenue Interest Purchase Agreement
The cash inflow from a revenue interest purchase agreement.
Recovery of Erroneously Awarded Compensation Disclosure [Line Items]
Debt instrument, face amount
Debt Instrument, Face Amount
Issuance of common stock from offering, net of issuance costs
Stock Issued During Period, Value, New Issues
Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label
Future Payment Milestone, Achievement of Drug Trial Outcomes Studies
The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study.
Royalty sale liability
Royalty Sale Liability, Current
Royalty Sale Liability, Current
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Summary of Total Stock Based Compensation Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Liability Related to the Revenue Interest Purchase Agreement
Liability Related to The Revenue Interest Purchase Agreement [Text Block]
The entire disclosure of liabilities related to the Revenue Interest Purchase Agreement entered into by the Company with Eiger III SA LLC ("Oberland").
Restatement Determination Date:
Restatement Determination Date [Axis]
Arrangements and Non-arrangement Transactions [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Title of 12(b) Security
Title of 12(b) Security
Concentration Risk Type [Axis]
Concentration Risk Type [Axis]
Common stock, $0.001 par value; 480,000,000 shares authorized as of March 31, 2025 and 480,000,000 shares authorized as of December 31, 2024; 198,654,569 shares issued at March 31, 2025 and 197,846,661 shares issued at December 31, 2024
Common Stock, Value, Issued
Share-based Payment Arrangement [Abstract]
Share-Based Payment Arrangement [Abstract]
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Purchase price (in dollars per share)
Class of Warrant or Right, Purchase Price Of Warrants Or Rights
Class of Warrant or Right, Purchase Price Of Warrants Or Rights
Certificates of deposit
Certificates of Deposit [Member]
Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested
Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]
Maximum annual contributions per employee, as a percentage of base salary
Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent
Maximum percentage of employee gross pay the employee may contribute to an employee stock purchase plan.
Debt instrument, convertible, threshold trading days
Debt Instrument, Convertible, Threshold Trading Days
Forfeited (in dollars per share)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Loss on debt extinguishment
Loss on extinguishment of debt
Gain (Loss) on Extinguishment of Debt
Increase in number of shares of common stock reserved for future issuance (in shares)
Common Stock, Capital Shares Reserved for Future Issuance, Increase
Common Stock, Capital Shares Reserved for Future Issuance, Increase
Financing activities
Net Cash Provided by (Used in) Financing Activities [Abstract]
Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested
Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March 31, 2025 and December 31, 2024
Preferred Stock, Value, Issued
Number of Options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
ESPP
Shares issuable related to the ESPP
Employee Stock [Member]
Convertible notes, net of issuance costs
Convertible Notes Payable, Noncurrent
Net loss per common share - basic (in dollars per share)
Net income (loss) per common share - basic (in dollars per share)
Earnings Per Share, Basic
Accounts payable
Increase (Decrease) in Accounts Payable
Proceeds from issuance of common stock, net of issuance costs
Proceeds from Issuance of Common Stock
Adjustment To PEO Compensation, Footnote
Adjustment To PEO Compensation, Footnote [Text Block]
Award Timing MNPI Disclosure
Award Timing MNPI Disclosure [Text Block]
Purchase of property and equipment not yet paid
Capital Expenditures Incurred but Not yet Paid
Aggregate Pension Adjustments Service Cost
Aggregate Pension Adjustments Service Cost [Member]
Amount of subsequent installment, subject to achievement of sales threshold
Amount of Subsequent Installment, Subject to Achievement of Sales Threshold
The amount of the subsequent installment which is subject to the achievement of the Sales Threshold as defined in the Revenue Interest Purchase Agreement.
Net (loss) income - basic
Net Income (Loss) Available to Common Stockholders, Basic
Proceeds from debt, net of issuance costs
Proceeds from Debt, Net of Issuance Costs
Compensation Actually Paid vs. Other Measure
Compensation Actually Paid vs. Other Measure [Text Block]
Total current liabilities
Liabilities, Current
Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year
Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]
Unrecognized stock-based compensation expense, options
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Other Accrued Liabilities
Other Liabilities Disclosure [Text Block]
Total assets
Assets
Concentration of Credit Risk
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Granted (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Unvested RSUs
Unvested Restricted Stock And Restricted Stock Units [Member]
Represents information pertaining to unvested restricted stock and restricted stock units.
Over-Allotment Option
Over-Allotment Option [Member]
Purchase of property and equipment
Payments to Acquire Property, Plant, and Equipment
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Commitments and contingencies (Note 5)
Commitments and Contingencies
Royalties
Royalty Rate On Net Sales
Royalty Rate On Net Sales
Termination Date
Trading Arrangement Termination Date
Wainwright
Wainwright [Member]
Wainwright
Class of Warrant or Right [Domain]
Class of Warrant or Right [Domain]
The Company and Basis of Presentation
Business Description and Basis of Presentation [Text Block]
Exercise price (in dollars per share)
Class of Warrant or Right, Exercise Price of Warrants or Rights
Fair value measurements
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, convertible, threshold percentage of stock price trigger
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger
2026
Long-Term Debt, Maturity, Year One
Stock Compensation
Share-Based Payment Arrangement [Text Block]
Non-cash interest expense related to the royalty sale liability
Non Cash Interest Expense Related To Royalty Sale Liability
Non Cash Interest Expense Related To Royalty Sale Liability
Capped Call
Capped Call [Member]
Capped Call
Entity Address, City or Town
Entity Address, City or Town
Debt Instrument [Axis]
Debt Instrument [Axis]
Summary of Activity Relating to the Company's Options and Performance-Based Options to Purchase Common Stock
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Amount of maximum annual contributions per employee
Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Amount
Maximum amount the employee may contribute to an employee stock purchase plan.
Total stock compensation expense
Share-Based Payment Arrangement, Expense
Net (loss) income
Net income (loss)
Net (loss) income
Net Income (Loss) Attributable to Parent
Trading Arrangement:
Trading Arrangement [Axis]
Investments, Debt and Equity Securities [Abstract]
Investments, Debt and Equity Securities [Abstract]
Payment to be received upon milestone
Cash Payment To Be Received Upon Certain Commercial Milestones
Cash Payment To Be Received Upon Certain Commercial Milestones
Granted (in dollars per share)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Pay vs Performance Disclosure, Table
Pay vs Performance [Table Text Block]
Forfeited (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Percentage of revenue interests payment on which agreement terminates
Percentage Of Revenue Interests Payment on Which Agreement Terminates
Percentage of revenue interests payment on which agreement terminates.
Milestone payment, first national health insurance price listing
Future Payment Milestone, First National Health Insurance Price Listing, Otsuka Territory
The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory.
Equity Awards Adjustments, Excluding Value Reported in Compensation Table
Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]
Oberland
Eiger Iii Sa Llc [Member]
Represents the information pertaining to revenue interest purchase agreement ("RIPA") with Oberland.
Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year
Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]
Entity File Number
Entity File Number
Convertible Senior Notes Due 2030, Subscription Transactions
Convertible Senior Notes Due 2030, Subscription Transactions [Member]
Convertible Senior Notes Due 2030, Subscription Transactions
Document Fiscal Year Focus
Document Fiscal Year Focus
Income Statement [Abstract]
Income Statement [Abstract]
Entity Address, Address Line One
Entity Address, Address Line One
Product Concentration Risk
Product Concentration Risk [Member]
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
Accrued other
Other Accrued Liabilities, Current
Total assets at fair value
Assets, Fair Value Disclosure
Name
Forgone Recovery, Individual Name
Exercisable
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Document Period End Date
Document Period End Date
Sale of Stock [Axis]
Sale of Stock [Axis]
Reserves
Inventory Valuation Reserves
Finished goods
Inventory, Finished Goods, Net of Reserves
Award Timing MNPI Considered
Award Timing MNPI Considered [Flag]
Cash payment
Contract With Customer, Liability, One Time Payment, Current
Potential one-time cash payments of up to $300 million upon the achievement of certain commercial milestones related to total net sales achievements in the DSE Territory.
Prepayment premium during year three
Debt Instrument, Prepayment Premium, Year Three
Debt Instrument, Prepayment Premium, Year Three
Outstanding and unvested at the beginning of period (in shares)
Outstanding and unvested at the ending of period (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Summary of Significant Accounting Policies
Significant Accounting Policies [Line Items]
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Insider Trading Arrangements [Line Items]
2025 Notes and 2030 Notes
2025 Notes and 2030 Notes [Member]
2025 Notes and 2030 Notes
Cash Equivalents
Cash and Cash Equivalents Disclosure [Text Block]
Capitalized Issuance costs amortized over next 12 months
Royalty Sale Liability, Capitalized Issuance Costs, Amortized Expense, Year One
Royalty Sale Liability, Capitalized Issuance Costs, Amortized Expense, Year One
Inventory Disclosure [Abstract]
Inventory Disclosure [Abstract]
Outstanding Aggregate Erroneous Compensation Amount
Outstanding Aggregate Erroneous Compensation Amount
PEO Actually Paid Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment to Compensation:
Adjustment to Compensation [Axis]
Other prepaid and current assets
Prepaid Expense and Other Assets, Current
Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]
Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]
Non-cash interest expense related to the revenue interest liability
Non Cash Interest Expense Related To Revenue Interest Liability
The amount of non-cash expense included in interest expense associated with the revenue interest liability.
Document Transition Report
Document Transition Report
Document Quarterly Report
Document Quarterly Report
Warrants
Warrants [Member]
Warrants
Fair Value, Recurring and Nonrecurring [Table]
Fair Value, Recurring and Nonrecurring [Table]
Customer [Domain]
Customer [Domain]
Entity Current Reporting Status
Entity Current Reporting Status
Accumulated Deficit
Retained Earnings [Member]
Amortization of debt issuance costs and discounts
Amortization of Debt Issuance Costs
Pension Adjustments Service Cost
Pension Adjustments Service Cost [Member]
Weighted-average shares outstanding - basic (in shares)
Weighted Average Number of Shares Outstanding, Basic
Stock Price or TSR Estimation Method
Stock Price or TSR Estimation Method [Text Block]
Subsidiary, Sale of Stock [Line Items]
Subsidiary, Sale of Stock [Line Items]
RSUs
Restricted Stock Units (RSUs) [Member]
Amortization of debt issuance costs and discounts
Amortization of Debt Issuance Costs and Discounts
Increase (Decrease) in Stockholders' Equity
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accrued professional fees
Accrued Professional Fees, Current
Executive Category:
Executive Category [Axis]
Name
Awards Close in Time to MNPI Disclosures, Individual Name
Revenue Benchmark
Revenue Benchmark [Member]
Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021
Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate
The minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021.
Entity Filer Category
Entity Filer Category
Warrant Amendment Agreements
Warrant Amendment Agreements [Member]
Warrant Amendment Agreements
Shares issuable upon conversion of convertible notes (in shares)
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Income Statement Location [Domain]
Statement of Income Location, Balance [Domain]
Company Selected Measure Name
Company Selected Measure Name